OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TNZTP55

Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS

Healthcare Facilities & ServicesVerified

The company maintains a strong capital structure with a debt-to-equity ratio of 0.05, indicating a low reliance on debt financing. However, its liquidity position is rated as medium, with negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. The company's return on equity (ROE) of 8.69% and return on assets (ROA) of 7.27% are both above the industry median, reflecting efficient use of equity and assets to generate returns. Profitability is robust, with a gross profit margin of 40.98% and an operating margin of 28.37%, both of which are strong indicators of cost control and pricing power. The company's net income margin of 20.29% is also well above the industry median, suggesting a healthy bottom line. These metrics align with the industry's preferred focus on operating efficiency and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts, which could impact revenue stability. The absence of segment or geographic breakdowns in the financial data limits the ability to assess risk distribution across different markets or product lines. Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the following year. The free cash flow of 614.91 million TRY supports reinvestment or shareholder returns, though the negative operating cash flow of -443.55 million TRY raises concerns about short-term cash generation. The risk assessment highlights a medium liquidity risk due to the negative net cash position after debt, which could constrain operational flexibility. The dilution risk is rated as low, with no significant dilution expected in the near term. However, the company's reliance on free cash flow for growth may necessitate future capital raising, which could introduce dilution pressure. Recent filings and transcripts do not provide specific details on strategic initiatives or major events, but the company's financial performance suggests a focus on maintaining profitability and managing debt levels. The absence of recent major announcements or regulatory actions indicates a relatively stable operating environment.

30-day price · TNZTP+2.92 (+12.9%)
Low$22.04High$29.78Close$25.60As of25 May, 00:00 UTC
Profile
CompanyTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
TickerTNZTP.IS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Tapdi Oksijen provides pharmaceutical and healthcare services, primarily generating revenue through the production and distribution of oxygen-related medical products and healthcare education services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

The company maintains a strong capital structure with a debt-to-equity ratio of 0.05, indicating a low reliance on debt financing. However, its liquidity position is rated as medium, with negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. The company's return on equity (ROE) of 8.69% and return on assets (ROA) of 7.27% are both above the industry median, reflecting efficient use of equity and assets to generate returns. Profitability is robust, with a gross profit margin of 40.98% and an operating margin of 28.37%, both of which are strong indicators of cost control and pricing power. The company's net income margin of 20.29% is also well above the industry median, suggesting a healthy bottom line. These metrics align with the industry's preferred focus on operating efficiency and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts, which could impact revenue stability. The absence of segment or geographic breakdowns in the financial data limits the ability to assess risk distribution across different markets or product lines. Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the following year. The free cash flow of 614.91 million TRY supports reinvestment or shareholder returns, though the negative operating cash flow of -443.55 million TRY raises concerns about short-term cash generation. The risk assessment highlights a medium liquidity risk due to the negative net cash position after debt, which could constrain operational flexibility. The dilution risk is rated as low, with no significant dilution expected in the near term. However, the company's reliance on free cash flow for growth may necessitate future capital raising, which could introduce dilution pressure. Recent filings and transcripts do not provide specific details on strategic initiatives or major events, but the company's financial performance suggests a focus on maintaining profitability and managing debt levels. The absence of recent major announcements or regulatory actions indicates a relatively stable operating environment.
Key takeaways
  • The company has a strong ROE and ROA, indicating efficient capital use and asset management.
  • A low debt-to-equity ratio suggests a conservative capital structure.
  • Negative net cash after debt raises liquidity concerns despite a medium liquidity risk rating.
  • Revenue concentration in a single segment increases exposure to market-specific risks.
  • Free cash flow is positive, supporting potential reinvestment or shareholder returns.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTRY
Revenue$3.43B
Gross profit$1.41B
Operating income$972.7M
Net income$695.7M
R&D
SG&A
D&A
SBC
Operating cash flow-$443.6M
CapEx-$278.8M
Free cash flow$614.9M
Total assets$9.57B
Total liabilities$1.56B
Total equity$8.01B
Cash & equivalents$0.00
Long-term debt$390.1M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$8.01B
Net cash-$390.1M
Current ratio1.6
Debt/Equity0.1
ROA7.3%
ROE8.7%
Cash conversion-64.0%
CapEx/Revenue-8.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricTNZTPActivity
Op margin28.4%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin20.3%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin41.0%45.5% medp25 31.1% · p75 62.9%below median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-8.1%-7.0% medp25 -14.9% · p75 -3.2%below median
Debt / equity5.0%25.0% medp25 3.8% · p75 63.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-25 01:11 UTC#5e3e14c4
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 18:13 UTCJob: ca530271